Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of teicoplanin to resisting Ebola virus

A technology of Ebola virus and teicoplanin, applied in the direction of antiviral agents, glycopeptide components, etc., can solve the problem of lack of vaccines and drugs for Ebola virus, achieve good antiviral effect and avoid long-term failure Effect

Active Publication Date: 2015-09-02
SUN YAT SEN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the world currently lacks effective vaccines and drugs against Ebola virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of teicoplanin to resisting Ebola virus
  • Application of teicoplanin to resisting Ebola virus
  • Application of teicoplanin to resisting Ebola virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 The inhibitory effect of different concentrations of antibiotic teicoplanin on Ebola virus envelope protein GP

[0025] (1) Encapsulated virus: Transfect pHIV-luc, pCMV-deltaR8.2 and EBOV-GP plasmids into 293T cells (10cm dish), collect virus supernatant after 48 hours, and measure p24.

[0026] (2) Infection: 293T cells in a 96-well plate were infected with p24-normalized HIV-luc / EBOV-GP pseudotype virus containing 8ug / ml Polybrene, and different concentrations of the antibiotic teicoplanin were added at the same time.

[0027] (3) Change medium: 12 hours after infection, replace with fresh DMEM medium.

[0028] (4) Detection of luciferase activity: 48 hours after infection, wash each well once with PBS, then add 100ul lysis buffer, shake for 30min, take 10ul lysate to detect luciferase activity.

Embodiment 2

[0029] Example 2 The inhibitory effect of different concentrations of the antibiotic teicoplanin on the envelope of vesicular stomatitis virus VSV-G

[0030] (1) Packed virus: transfect pHIV-luc, pCMV-deltaR8.2 and VSV-G plasmids into 293T cells (10cm dish), and after 48 hours, collect the virus supernatant and measure p24.

[0031] (2) Infection: 293T cells in a 96-well plate were infected with p24-normalized HIV-luc / VSV-G pseudotype virus containing 8ug / ml Polybrene, and different concentrations of the antibiotic teicoplanin were added at the same time.

[0032] (3) Change medium: 12 hours after infection, replace with fresh DMEM medium.

[0033] (4) Detection of luciferase activity: 48 hours after infection, wash each well once with PBS, then add 100ul lysis buffer, shake for 30min, take 10ul lysate to detect luciferase activity.

[0034] According to the results of Example 1 and Example 2, the antibiotic teicoplanin can specifically act on the envelope protein EBOV-GP of ...

Embodiment 3

[0035] Example 3 Toxicity CC50 test

[0036] MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium, inner salt) is a newly synthesized tetrazole with The application principle of MTT is the same, that is, it is reduced to colored formazan products by various dehydrogenases in the mitochondria of living cells, and its color depth is highly correlated with the number of living cells of some sensitive cell lines within a certain range. According to the measured absorbance value (OD value) at 490n, the number of viable cells is judged. The larger the OD value, the stronger the cell activity, and the less toxic the drug.

[0037] (1) Inoculate cells, use DMEM culture medium containing 10% fetal calf serum to prepare 293t into a single cell suspension, inoculate 1000 cells per well into a 96-well plate, and the volume of each well is 200ul

[0038] (2) Add the antibiotic teicoplanin after 24 hours of wall attachment, 2 μl per well, and the fina...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of teicoplanin to resisting Ebola virus. The teicoplanin can inhibit the envelope protein GP of Ebola virus. The envelope protein GP is the Zaire envelope protein of Ebola virus breaking out in 2014. The teicoplanin can inhibit Ebola virus from entering host cells and acting in host cells.

Description

technical field [0001] The present invention relates to a new application of antiviral drugs, more specifically, relates to an application of teicoplanin in anti-Ebola virus. Background technique [0002] In 2014, the Ebola virus broke out in many countries in West Africa, and it has claimed the lives of thousands of innocent people. This is the most significant, severe and complex outbreak of Ebola in the history of nearly four decades. Before the outbreak of Ebola, the virus was found in Africa in 1976 and then quickly retreated into the jungle. Until now, this humble Ebola virus still devours the lives of infected people at an extremely rare rate, with almost no resistance. The development of drugs is so urgent that even drugs and vaccines that have not yet been approved have been put into battle. Ebola virus is a class of filoviruses with an envelope and a single-stranded antisense RNA genome, and its infection can cause severe viral hemorrhagic fever in humans and non...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/14A61P31/14
Inventor 潘婷张辉周南
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com